Careers  |  Sign In  |  Register

Dr. Hamid on Promising Triplet Combinations Under Exploration in Melanoma

In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that suggests progression-free survival (PFS) is increased with the use of these targeted therapies.

Learn more by clicking here.